Apoptin enhances the oncolytic properties of Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2011-08-24 / Intervirology 2012;55(4):276-86HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-40Immunotherapy for prostate cancer: biology and therapeutic approaches
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-85Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells
/in Gastric Cancer, Hyperthermia, International Publications /von 2011-08-07 / J. Huazhong Univ. Sci. Technol. Med. Sci. 2011 Aug;31(4):488Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
/in Acute Leukemia, Dendritic Cells, International Publications /von 2011-08-04 / Ger Med Sci 2011;9:Doc18Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
/in Dendritic Cells, International Publications /von 2011-08-01 / Immunol. Res. 2011 Aug;50(2-3):235-47Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1
/in Dendritic Cells, HIV/AIDS, International Publications /von 2011-07-23 / Vaccine 2011 Sep;29(38):6454-63Treatment of high-grade glioma in children and adolescents
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-07-22 / Neuro-oncology 2011 Oct;13(10):1049-58
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de